DaVita (NYSE:DVA) Announces Quarterly Earnings Results

DaVita (NYSE:DVA) posted its quarterly earnings data on Thursday. The company reported $3.82 earnings per share for the quarter, topping analysts’ consensus estimates of $3.57 by $0.25, FiscalAI reports. The company had revenue of $3.58 billion during the quarter, compared to analysts’ expectations of $3.52 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period last year, the firm earned $2.51 EPS.

Here are the key takeaways from DaVita’s conference call:

• Integrated Kidney Care (IKC) is outperforming expectations, with 2026 adjusted operating income now expected to be at least $65 million—$25 million above prior guidance and $45 million above 2025. DaVita cited improving savings rates, lower hospital utilization and the new Humana partnership as growth drivers.
• DaVita will begin the national rollout of its expanded HD dialyzer next week, following pilots across 150 centers involving more than 10,000 patients. More than 90% of eligible pilot patients adopted the technology, though meaningful mortality and volume benefits are not expected until the second half of 2028.
• Third-quarter treatment volume increased 1.2% year over year, supported by a roughly 1% rise in patient census as mortality improves. The company expects 2027 volume growth to exceed 2026 levels, although Q4 faces an approximately 1% unfavorable day-mix effect.
• DaVita narrowed its 2026 outlook to adjusted operating income of $2.175 billion-$2.25 billion and adjusted EPS of $14.30-$15.20, reflecting higher-than-planned U.S. dialysis costs—particularly technology spending that grew more than 20% year over year. Commercial mix pressure from expiring ACA enhanced premium tax credits is expected to create a roughly $40 million headwind.
• The finalized 2027 ESRD rule is estimated to provide a 1.5%-2% full-year net rate benefit, but the reported 3.5% Q1 increase for large dialysis organizations will decline materially after the first quarter as TDAPA payments are recalculated quarterly. DaVita said the impact is driven mainly by DefenCath rather than phosphate binders.

DaVita Stock Performance

Shares of NYSE:DVA traded down $11.47 during trading hours on Friday, hitting $181.84. 925,656 shares of the company’s stock traded hands, compared to its average volume of 893,076. The company has a market cap of $11.60 billion, a price-to-earnings ratio of 14.89, a price-to-earnings-growth ratio of 0.48 and a beta of 0.80. The company’s fifty day simple moving average is $181.13 and its two-hundred day simple moving average is $176.11. DaVita has a 52 week low of $101.00 and a 52 week high of $247.49.

Key Headlines Impacting DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita reported third-quarter adjusted EPS of $3.82, above the $3.57 consensus estimate, while revenue increased 4.6% year over year to $3.58 billion, exceeding expectations of $3.52 billion. DaVita Q3 adjusted EPS report
• Positive Sentiment: Earnings growth was supported by strength in the company’s integrated kidney care business and international operations. Net income attributable to common shareholders rose 48.3% to $222.9 million, and adjusted earnings increased sharply from $2.51 per share a year earlier. DaVita Q3 earnings beat report
• Neutral Sentiment: Management’s results showed mixed operating momentum: gross profit increased, but operating profit fell 1.3% year over year. Operating cash flow also declined to $518.8 million, while capital expenditures totaled $159.5 million. DaVita Q3 2026 financial results
• Negative Sentiment: A reported $62 million China-related charge, along with rising costs and margin pressure, overshadowed the earnings and revenue beats. These items raised concerns about the durability of profit growth and contributed to the stock’s decline. DaVita Q3 China charge report
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of DaVita investors, adding a headline risk even though the notice did not allege a specific finding of wrongdoing. Pomerantz DaVita investor investigation

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DVA. Oppenheimer set a $220.00 price target on shares of DaVita in a report on Friday, August 7th. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. UBS Group lifted their price objective on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Barclays upped their target price on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Finally, TD Cowen reissued a “buy” rating on shares of DaVita in a research note on Wednesday, October 21st. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, DaVita has an average rating of “Moderate Buy” and an average target price of $233.43.

About DaVita

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.